0001564590-21-021082.txt : 20210428 0001564590-21-021082.hdr.sgml : 20210428 20210428061133 ACCESSION NUMBER: 0001564590-21-021082 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210427 ITEM INFORMATION: Other Events FILED AS OF DATE: 20210428 DATE AS OF CHANGE: 20210428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 21861211 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 abmd-8k_20210427.htm 8-K abmd-8k_20210427.htm
false 0000815094 0000815094 2021-04-27 2021-04-27

-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2021

 

ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-09585

04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

22 Cherry Hill Drive
Danvers, Massachusetts 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ABMD

The NASDAQ Stock Market LLC

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 



 

Item 8.01

Other Events.

 

Centers for Medicare & Medicaid Services (CMS) Proposed Rule for the Inpatient Prospective Payment System (IPPS)

 

On April 27, 2021, the Centers for Medicare and Medicaid Services (CMS) released a draft of proposed Medicare payment levels for inpatient hospital discharges for fiscal year 2022 (October 1, 2021 through September 30, 2022).  We are pleased and support the proposed rule coding changes to provide stability to the other heart assist system implants, MS-DRG 215.  CMS is proposing to reassign select ICD-10-PCS codes from MS-DRG 215 to additional cardiovascular related MS-DRGs to align clinical populations and better reflect hospital resources.

 

Proposed payment levels for all hospital MS-DRGs, including those most relevant to Impella related procedures, are in Table A. The final rulemaking may differ substantially from this proposal and will take effect on October 1, 2021. Hospitals that incorporate best practices often achieve better patient outcomes at a lower cost of care. For the sickest patients who utilize extensive resources, hospitals are eligible to receive additional outlier payments, which may collectively increase reimbursement in future years.

 

The American Hospital Association (AHA) and CMS have established a system of care around the utilization of percutaneous heart pumps. The history and creation of this dedicated payment system with Impella implant/explant, bi-ventricular, ECPella, and transfer reimbursement allow some of the most critically ill patients the potential to survive and achieve native heart recovery.

 

As highlighted by CMS, the FDA has granted Abiomed EUAs for COVID-19. It should be noted for the duration of the public health emergency (PHE), hospitals treating patients diagnosed with COVID-19 receive an additional 20% in reimbursement.

 

The Proposed Rule for the Inpatient Prospective Payment System (IPPS) is available on the CMS website at cms.gov and is open for public comment until June 28, 2021.

 

Table A. Summary of common MS-DRGs from the Proposed Rule for illustration only.

 

Common Impella Procedures *

 

 

 

Current Rate

 

 

Proposed Rate

 

 

Current Rate

 

 

Proposed Rate Oct 1, 2021

 

 

 

MS-DRG

 

(All Hospitals)

 

 

(All Hospitals)

 

 

(Sample 100 Impella sites)

 

 

(Sample 100 Impella sites)

 

Biventricular Impella or open insertion with removal

 

1

 

$

186,796

 

 

$

191,165

 

 

$

217,989

 

 

$

223,120

 

ECPella

 

3

 

$

122,456

 

 

$

126,297

 

 

$

143,221

 

 

$

147,713

 

Uni-Ventricular Impella percutaneous insertion

 

215

 

$

71,947

 

 

$

69,834

 

 

$

84,407

 

 

$

81,928

 

Intraoperative Impella procedures with MCC

 

216

 

$

67,254

 

 

$

66,403

 

 

$

79,117

 

 

$

78,116

 

Intraoperative Impella procedures with CC

 

217

 

$

41,866

 

 

$

42,881

 

 

$

49,560

 

 

$

50,762

 

ICU care and removal of Impella, after transfer from outlying hospital

 

268

 

$

44,843

 

 

$

46,056

 

 

$

53,065

 

 

$

54,500

 

 

* Actual MS-DRGs may vary based on procedure, estimated hospital relative weight.

MCC, Major Complications; CC, Comorbid Condition

All Hospitals’ include ~3,200 Medicare hospitals, and only ~1,788 have cath labs or operating rooms.

Additional MS-DRGs 218-221 may also have nominal case volume with reassignment



 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

 

/s/ Marc A. Began

 

 

 

 

 

 

Marc A. Began

Vice President, General Counsel and Secretary

 

Date: April 28, 2021

 

 

 

 

 

 

 

 

 

GRAPHIC 2 gfp4job2mu0x000001.jpg GRAPHIC begin 644 gfp4job2mu0x000001.jpg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end EX-101.SCH 3 abmd-20210427.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 abmd-20210427_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 5 abmd-20210427_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 abmd-8k_20210427_htm.xml IDEA: XBRL DOCUMENT 0000815094 2021-04-27 2021-04-27 false 0000815094 8-K 2021-04-27 ABIOMED, Inc. DE 001-09585 04-2743260 22 Cherry Hill Drive Danvers MA 01923 (978) 646-1400 Common Stock, $0.01 par value ABMD NASDAQ false false false false false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Apr. 27, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 27, 2021
Entity Registrant Name ABIOMED, Inc.
Entity Central Index Key 0000815094
Entity Emerging Growth Company false
Entity File Number 001-09585
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-2743260
Entity Address, Address Line One 22 Cherry Hill Drive
Entity Address, City or Town Danvers
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01923
City Area Code (978)
Local Phone Number 646-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.01 par value
Trading Symbol ABMD
Name of each exchange on which registered NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports abmd-8k_20210427.htm abmd-20210427.xsd abmd-20210427_lab.xml abmd-20210427_pre.xml gfp4job2mu0x000001.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abmd-8k_20210427.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "abmd-8k_20210427.htm" ] }, "labelLink": { "local": [ "abmd-20210427_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abmd-20210427_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abmd-20210427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abmd", "nsuri": "http://www.abiomed.com/20210427", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20210427.htm", "contextRef": "C_0000815094_20210427_20210427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20210427.htm", "contextRef": "C_0000815094_20210427_20210427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210427/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-21-021082-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-021082-xbrl.zip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end